News | April 03, 2013

Early COPD Diagnosis Possible with Nuclear Medicine

V/Q imaging has the potential to study and diagnose the early stages of COPD

In vivo ventilation/perfusion (V/Q) imaging

April 3, 2013 — In vivo ventilation/perfusion (V/Q) imaging can detect early changes to the lung caused by cigarette smoke exposure and provides a noninvasive method for studying lung dysfunction in preclinical models, according to research published in the April issue of The Journal of Nuclear Medicine. These measures have the potential to be applied clinically to study and diagnose the early stages of chronic obstructive pulmonary disease (COPD).

“Our preclinical study suggests that not only can V/Q imaging detect early and small changes in lung pathology, the type of V/Q mismatching could provide insight into the underlying pathologies, which current measures of lung function are unable to do,” said N. Renee Labiris, Ph.D., one of the authors of the study “Detection of Lung Dysfunction Using Ventilation and Perfusion SPECT in a Mouse Model of Chronic Cigarette Smoke Exposure.”

In the study, groups of mice were exposed to cigarette smoke for 50 minutes twice daily, five days a week, for either eight or 24 weeks. Age-matched control groups of mice were also included in the study for comparison. After the final cigarette smoke exposure, V/Q single photon emission computed tomography (SPECT) was performed, followed by a computed tomography (CT) scan. Histologic lung sections were then collected and a semiautomated quantitative analysis of airspace enlargement was applied to whole histology slices.

Upon analysis, functional impairment was noted in the lungs due to increased inflammation and airspace enlargement. This functional impairment, measured with SPECT V/Q imaging, identified COPD characteristics before CT was able to detect structural changes in the lungs. In addition, V/Q mismatching progressively increased during cigarette smoke exposure in mice compared to age-matched control mice and offered insight into the underlying pathology causing COPD.

“V/Q imaging is a common nuclear medicine technique, and SPECT/CT systems are increasingly used in clinical practice,” said Labiris. “As such, the technology examined in this study can be carried out in both preclinical and clinical settings, enabling researchers to translate preclinical investigations of disease, associated functional abnormalities and future drug targets into an improved understanding and management of the disease in patients.”

For more information: www.snmmi.org

 

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init